卵圆孔未闭相关卒中潜在致病机制命名与分类更新提案
该文指出卵圆孔未闭约导致5%的缺血性卒中及10%的中青年卒中,随机临床试验显示对隐源性卒中合并PFO者行PFO封堵预防复发优于单纯抗血小板,且抗凝可能优于抗血小板。基于此,作者提出修订PFO相关卒中的命名与分类框架,并更新三大卒中分型算法。
要点
- PFO封堵预防隐源性卒中复发优于单纯抗血小板治疗。
- 医学治疗中抗凝可能优于抗血小板药物。
- 需更新PFO相关卒中的命名与分类框架。
核心结论
- 新证据支持更新PFO相关卒中的致病机制分类体系。
研究设计与样本
- 基于随机临床试验证据的命名与分类提案。
主要发现
- PFO约导致5%的缺血性卒中及10%的中青年卒中。
- PFO封堵预防卒中复发优于单纯抗血小板治疗。
- 抗凝可能优于抗血小板药物。
关键数值与推荐
- PFO封堵适用于PFO合并隐源性指数缺血性卒中的复发预防。
临床怎么用
- 对隐源性卒中合并PFO患者应考虑PFO封堵预防复发。
- 医学治疗中可考虑抗凝优于抗血小板。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recent epidemiologic and therapeutic advances have transformed understanding of the role of and therapeutic approach to patent foramen ovale (PFO) in ischemic stroke. Patent foramen ovale is likely responsible for approximately 5% of all ischemic strokes and 10% of those occurring in young and middle-aged adults. OBSERVATIONS: Randomized clinical trials have demonstrated that, to prevent recurrent ischemic stroke in patients with PFO and an otherwise-cryptogenic index ischemic stroke, PFO closure is superior to antiplatelet medical therapy alone; these trials have provided some evidence that, among medical therapy options, anticoagulants may be more effective than antiplatelet agents. CONCLUSIONS AND RELEVANCE: These new data indicate a need to update classification schemes of causative mechanisms in stroke, developed in an era in which an association between PFO and stroke was viewed as uncertain. We propose a revised general nomenclature and classification framework for PFO-associated stroke and detailed revisions for the 3 major stroke subtyping algorithms in wide use.
引用
- Elgendy AY, Saver JL, Amin Z, et al. Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke. JAMA Neurol. 2020. PMID: 32282016. doi:10.1001/jamaneurol.2020.0458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。